Navigation Links
Researchers report first success of targeted therapy in most common non-small cell lung cancer
Date:11/28/2012

BOSTON - A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists is the first to demonstrate that chemotherapy and a new, targeted therapy work better in combination than chemotherapy alone in treating patients with the most common genetic subtype of lung cancer.

Published online today in The Lancet Oncology, the combination of chemotherapy and the targeted drug selumetinib was more effective than chemotherapy alone in a clinical trial involving patients with a form of non-small cell lung cancer (NSCLC) that carries a mutation in the gene KRAS a variety that represents about 20 percent of all NSCLC cases. Previously, no targeted agent, either alone or in combination with another drug, had proven beneficial in a trial involving patients with this type of NSCLC.

The 87 patients who participated in the new, phase II trial conducted at 67 sites around the world had advanced, KRAS-mutant NSCLC that had failed initial chemotherapy. The participants were randomly assigned to receive either selumetinib and the chemotherapy agent docetaxel or docetaxel alone.

Investigators found that while 37 percent of the patients in the selumetinib group experienced some shrinkage of their tumor, none of the patients in the docetaxel-only group did. Of particular significance, patients receiving selumetinib lived a median of 5.3 months before their cancer began to worsen, compared to 2.1 months for those receiving chemotherapy alone. (Patients in the selumetinib group also survived longer, on average, than those in the docetaxel group 9.4 months compared to 5.2 months but the improvement was not considered statistically significant.)

"Our findings suggest that selumetinib and docetaxel work synergistically each enhancing the effect of the other," says the study's lead author, Pasi A. Janne, MD, PhD, of Dana-Farber. "This opens the possibility that there may finally be a therapeutic strategy using a targeted therapy which could be clinically effective in this population of KRAS-mutant lung cancer patients."

Some side effects, including neutropenia (a white blood cell deficiency), neuropenia plus fever, shortness of breath, and loss of strength, were more common in the selumetinib group than the other.

Researchers and physicians will need to work on ways of managing these problems with patients, Jnne said.

NSCLC tumors with KRAS mutations are more common in current and former smokers than in those who have never smoked, and occur at a higher rate in Caucasians than in others. The study findings are especially noteworthy because mutated KRAS regardless of the type of tumor it appears in has been one of the most difficult genes to block with targeted therapies.

Selumetinib circumvents that problem by targeting not KRAS itself, but one of the gene's co-conspirators, a protein called MEK that is indirectly activated by KRAS.

"The opportunity now is to validate this approach in further clinical trials so it can be developed into a real therapy for patients," Jnne remarks. "Given that KRAS mutations are common in other cancers (found in 90 percent of pancreatic cancers and 40 percent of colon cancers), our findings may be useful in developing therapies for patients with these cancers as well."


'/>"/>

Contact: Robbin Ray
Robbin_Ray@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert  

Related medicine news :

1. USC, Oxford researchers find high fructose corn syrup-global prevalence of diabetes link
2. Researchers study cry acoustics to determine risk for autism
3. Researchers explore social media as preventative method for infectious diseases
4. New mechanism for cancer progression discovered by UNC and Harvard researchers
5. Researchers identify physiological evidence of chemo brain
6. Researchers find chemical switches for neurodegenerative diseases
7. Release all Tamiflu data as promised, argue researchers
8. Researchers link new molecular culprit to breast cancer progression
9. Researchers discover gender-based differences in Alzheimers disease
10. Researchers find evidence that brain compensates after traumatic injury
11. Researchers find decline in availability and use of key treatment for depression
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers report first success of targeted therapy in most common non-small cell lung cancer
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... announces its inaugural health care blockchain event, Distributed: Health, to be held in ... Nashville’s downtown Symphony Center. , A 24-hour Hackathon preceding the event will host ...
(Date:5/24/2016)... ... May 24, 2016 , ... Fire Door Solutions, headquartered in ... from start to finish, for Life Safety compliance. These expanded services include ... by the Joint Commission, and fire stopping reviews, inspections, and repairs. Clients ...
(Date:5/24/2016)... ... May 24, 2016 , ... Jericho Project has named ... role she will be responsible for fundraising and communications for the nationally-acclaimed nonprofit, working ... of Jericho Project working to end homelessness at its roots. , “LaToya Williams-Belfort ...
(Date:5/24/2016)... CO (PRWEB) , ... May 24, 2016 , ... ... tied to family wealth and to housing, with more advantaged communities providing richer ... proposed five types of interventions: (a) school improvement policies; (b) school choice policies; ...
(Date:5/24/2016)... ... May 24, 2016 , ... New Brunswick, New Jersey: This year marks ... reach their fullest potential. To commemorate the anniversary, the hospital has themed the milestone ... Roll for Children’s Specialized Hospital Foundation on Saturday, May 21, at Johnson Park in ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... KONG , May 24, 2016 ... stent de doble terapia del mundo, introduce catéteres ... arteriovenosa. OrbusNeich, una compañía global especializada ... las vidas, ha expandido su cartera incluyendo productos ... balón JADE™ y Scoreflex™ PTA son los dispositivos ...
(Date:5/24/2016)... May 24, 2016 Open Access ... Clinical Neurophysiology  Elsevier , a world-leading ... services, today announced the launch of Clinical ... journal that focuses on clinical practice issues in clinical ... clinical series, normal values and didactic reviews. It is ...
(Date:5/24/2016)... , May 24, 2016 ... elkaar verbindt, zodat zij collectief patiënten kunnen behandelen, hun ... is het idee achter de nieuwe en revolutionaire MDLinking ... van de Nederlandse vaatchirurg dr. Hans Flu en oncologisch ... app, die inmiddels beschikbaar is, wordt op dinsdag 24 ...
Breaking Medicine Technology: